$Amazing $Biotech & $olid $Microcap $tocks

[ash111]

kei, did you know that CBLI received a green light both FDA and EMA?. the meaning is two huge markets (US & EU, actually the rest of world will follow on any approval). btw. EU been facing more Radiation Risks, Hence I believe EU could provide much more Value. there are a few competitors but CBLI has already completed some human trials!! and The FDA already has granted Entolimod (CBLB502) both Fast Track and Orphan Drug status!.

April 2017 positive opinion from both the European Medicines Agency (EMA) and the U.S. Food and Drug Administration’s (FDA) :

1. Cleveland BioLabs Announces Commencement of In Vivo Biocomparability Study. "We are excited to have received agreement from the FDA to commence the in vivo biocomparability study,"

2. Cleveland BioLabs Announces European Medicines Agency Positive Opinion Regarding the Entolimod Pediatric Investigation Plan. "provide a path toward product labeling for children. The future work to be performed as part of the PIP can be deferred until after an MAA submission".

3. Dods and BAEDA plop down about $80m so far.

4. beside P3, several drugs Phase including 2 Final Data January 2018
https://clinicaltrials.gov/ct2/show/NCT02844699?term=M-VM3&rank=2
be sure share price will react Respectively before January 2018.

5. and finally, a very positive coverage from Analysts: in 2013, Edison valued the company at $100M while in 2017 company gettin closer commercialization.

Jarrod Wesson back in April 2017 wrote :

* "Investors should remark that the company owns two drugs in Phase 2 as well as the Entolimod-Biodefense that is in Phase 3"

* "the balance sheet looks very clean right now. The company showed in the last 10-k that it had about $15 million in total assets and only $3 million in total liabilities. It is also remarkable that the company has no long term debt, and 99% of its assets are short-term investments or cash on hand".

* "Cleveland BioLabs is very close to commercializing its new drug Entolimod and has other drugs in Phase 2".
in this case I think most would agree that $30m company could easily shift into high gear towards $300-$500m company relating this blockbaster potential drug.